Dr. Carlos Alemany
Claim this profileAdventHealth Orlando
Expert in Breast Cancer
Studies Breast cancer
22 reported clinical trials
62 drugs studied
About Carlos Alemany
Education:
- Earned an MD from Ponce School of Medicine, Ponce, Puerto Rico.
Experience:
- Completed both residency and fellowship at Cleveland Clinic Foundation, Cleveland, OH.
- Specializes in hematology and oncology with a focus on breast cancer and genitourinary malignancies.
- Has been recognized as one of the Best Doctors in America annually since 2009.
- Serves as an associate professor at the University of Central Florida.
- Fluent in both English and Spanish.
Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 positive
Stage III
2Breast Cancer
HER2 positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Carlos Alemany is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
More about Carlos Alemany
Clinical Trial Related5 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Carlos Alemany has experience with
- Trastuzumab
- Pertuzumab
- Pembrolizumab
- Placebo
- Tucatinib
- Leucovorin Calcium
Breakdown of trials Carlos Alemany has run
Breast Cancer
Breast cancer
Cancer
Stomach Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Carlos Alemany specialize in?
Carlos Alemany focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Carlos Alemany currently recruiting for clinical trials?
Yes, Carlos Alemany is currently recruiting for 8 clinical trials in Orlando Florida. If you're interested in participating, you should apply.
Are there any treatments that Carlos Alemany has studied deeply?
Yes, Carlos Alemany has studied treatments such as Trastuzumab, Pertuzumab, Pembrolizumab.
What is the best way to schedule an appointment with Carlos Alemany?
Apply for one of the trials that Carlos Alemany is conducting.
What is the office address of Carlos Alemany?
The office of Carlos Alemany is located at: AdventHealth Orlando, Orlando, Florida 32803 United States. This is the address for their practice at the AdventHealth Orlando.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.